ArsenalBio is undergoing a significant restructuring, laying off 99 employees to focus on in vivo CAR-T therapy. This strategic shift involves halting development of the company's ex vivo clinical assets. The biotech was once a strong fundraiser, securing substantial investments and partnerships. The company is now seeking new opportunities for its existing technology and assets. This move places ArsenalBio in a competitive field with several established players.
San Francisco, California
https://www.fiercebiotech.com/biotech/arsenalbio-sheds-most-staff-pivot-vivo-car-t